HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahmed, C. M. Articles by Johnson, H. M. Search for Related Content PubMed PubMed Citation Articles by Ahmed, C. M. Articles by Johnson, H. M.

IFN Mimetic as a Therapeutic for Lethal Vaccinia Virus Infection: Possible Effects on Innate and Adaptive Immune Responses¹

Department of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611

We have developed small peptide mimetics of IFN- that can bypass the poxvirus virulence factor B8R protein, which binds to intact IFN- and prevents its interaction with receptor extracellular domain. Thus, these peptides inhibit vaccinia virus replication in cell culture where intact IFN- is ineffective. We demonstrate here that the mouse IFN--mimetic peptide, IFN-_95–132, protects C57BL/6 mice against overwhelming lethal vaccinia virus infection. The mimetic peptide was synthesized with an attached lipophilic group for penetration of cell plasma membrane. Injection of mimetic i.p. before and at the time of intranasal (10⁶ PFU) or i.p. (10⁷ PFU) challenge with virus resulted in complete protection at 200 µg of mimetic and 40–60% protection at 5 µg of mimetic. Initiation of treatment of mice with IFN- mimetic up to 2 days postinfection resulted in complete protection against death, whereas initiation of treatment at 6 days postinfection resulted in 40% protection. Administration of mimetic by the oral route also completely protected mice against the intranasal route of a lethal dose of vaccinia virus challenge. In addition to its direct antiviral effect, the mimetic also possessed adjuvant effects in boosting humoral and cellular immunity to vaccinia virus. The combination of antiviral and adjuvant effects by the IFN mimetic probably plays a role in its potent anti-vaccinia virus properties. These results suggest an effective therapeutic against ongoing, lethal poxvirus infections that taps into innate and adaptive host defenses.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grant AI 56152 and Department of Defense Grant W911NF-05-1-0170 (both to H.M.J.).

² Address correspondence and reprint requests to Dr. Chulbul M. Ahmed, Department of Microbiology and Cell Science, University of Florida, Building 981, Room 1052, Museum Road, P.O. Box 110700, Gainesville, FL 32611. E-mail address: ahmed1{at}ufl.edu

³ Abbreviations used in this paper: mIFN-, murine IFN-; NLS, nuclear localization sequence.

This article has been cited by other articles:

				C. M. Ahmed, R. Dabelic, L. W. Waiboci, L. D. Jager, L. L. Heron, and H. M. Johnson SOCS-1 Mimetics Protect Mice against Lethal Poxvirus Infection: Identification of a Novel Endogenous Antiviral System J. Virol., February 1, 2009; 83(3): 1402 - 1415. [Abstract] [Full Text] [PDF]